Please login to the form below

Not currently logged in
Email:
Password:

Neovii Pharmaceuticals promotes Juergen Pohle to CEO

He will take over from Alexandre Sudarskis in January

Neovii Pharmaceuticals Juergen PohleSwiss biopharmaceutical company Neovii Pharmaceuticals has promoted its chief commercial officer Juergen Pohle to managing director and CEO.

He will assume the new role in January, when it takes over from outgoing CEO Alexandre Sudarskis who will continue at the firm as an executive director and member of its board.

David Fuhrer said: "Juergen's leadership skills, his long-term proven track record and his many years of international experience in the pharmaceutical industry make him the ideal candidate for the position of CEO.

“We are extremely pleased that Juergen has embraced the challenge of further driving the development and growth of Neovii."

Pohle has served as Neovii’s chief commercial officer of Pharmaceuticals since 2016 and has over 25 years of experience in the pharmaceutical industry, having previously worked at Bayer HealthCare, GlaxoSmithKline and Novartis.

Prior to joining Neovii he headed up Novartis’ emerging growth markets and institutional customers businesses.

18th September 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics